Cigna is building on client demand ... announced on Thursday that it had inked a deal with Danish drugmaker Novo Nordisk, which manufactures the GLP-1 Wegovy, to give Wegovy preferred placement ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk (NVO) and Eli Lilly (NYSE ...

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound ... numerous forays into the GLP-1 space. Last year, the company ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. Adding 5m GLP-1 patients at slightly lower prices or 21m at LLY price levels both lead ...

Cigna sales ... fair and affordable price," Cordani said. "In fact, pharmacy benefit companies are the only part of the drug supply chain who work to drive cost down." GLP-1 agonists and related ...

24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered ... would “substantially lower” GLP-1 prices in the U.S. Mr. Jørgensen ...

When government officials and politicians scrutinize high U.S. drug prices ... not limit coverage if Novo were to cut the list prices of its massively popular GLP-1 drugs. Cigna Group, CVS ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that ...

Cigna is building on client demand for tools to support patients on GLP-1 weight loss drugs ... are put off by the medications’ steep list prices and unpredictable long-term outcomes, according ...